<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04480762</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1703-101</org_study_id>
    <nct_id>NCT04480762</nct_id>
  </id_info>
  <brief_title>A Trial of SHR-1703 in Healthy Adults</brief_title>
  <official_title>A Randomised, Double Blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1703 Injection Administered Subcutaneously in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SHR-1703 is a monoclonal antibody under development for severe asthma. This study is the&#xD;
      first study in Healthy subjects. The purpose of this study is to evaluate the safety,&#xD;
      tolerability, pharmacokinetics and pharmacodynamics of a single dose SHR-1703 administered&#xD;
      subcutaneously in Chinese healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted at 1 study center in China. Approximately 42 healthy Chinese&#xD;
      male and female subjects, aged 18 to 55 inclusive, will be randomized to receive a single SC&#xD;
      administration of SHR-1703: Treatment 1, Treatment 2, Treatment 3, Treatment 4 and Treatment&#xD;
      5. Each subject will participate in only 1 treatment group. The total length of the study for&#xD;
      each subject is up to 190 days (28 days of screening and 155+/- 7 days of further study&#xD;
      visits).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Actual">September 21, 2021</completion_date>
  <primary_completion_date type="Actual">September 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>From Day 1 to Days 155</time_frame>
    <description>The number and percentage of subjects with treatment-emergent AE/SAE/AE by severity/drug-related AE/drug-related SAE/death in each dose level group and overall. AE/SAE will be displayed by MedDRA SOC and/or PT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as determined by abnormality in haematology</measure>
    <time_frame>From Day 1 to Days 155</time_frame>
    <description>Measurement of red blood cell count, white blood cell count, haemoglobin and platelets</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as determined by abnormality in clinical chemistry</measure>
    <time_frame>From Day 1 to Days 155</time_frame>
    <description>Measurement of kidney function (e.g.urea ,creatinine, Uric acid), liver function(ALP, ALT, AST, albumin, total bilirubin), lipid profile(total cholesterol, triglycerides), ions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as determined by abnormality in urinalysis</measure>
    <time_frame>From Day 1 to Days 155</time_frame>
    <description>Measurement of glucose, ketones, leukocytes, blood and protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as determined by evaluation of blood pressure in mmHg</measure>
    <time_frame>From Day 1 to Days 155</time_frame>
    <description>Measurement of blood pressure (systolic and diastolic in mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as determined by evaluation of Pulse rate in beats per minute</measure>
    <time_frame>From Day 1 to Days 155</time_frame>
    <description>Measurement of Pulse rate in beats per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as determined by evaluation of body temperature in degree Celsius</measure>
    <time_frame>From Day 1 to Days 155</time_frame>
    <description>Measurement of body temperature in degree Celsius</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as determined by evaluation of Respiratory rate in beats per minute</measure>
    <time_frame>From Day 1 to Days 155</time_frame>
    <description>Measurement of Respiratory rate in beats per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as determined by analysis of 12-lead ECG variables: heart rate (beats per minute)</measure>
    <time_frame>From Day 1 to Days 155</time_frame>
    <description>The ECG variables will be summarized by absolute value at each visit by treatment group, together with the corresponding changes from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as determined by analysis of 12-lead ECG variables: PR, QRS, QT and QTcF (milliseconds)</measure>
    <time_frame>From Day 1 to Days 155</time_frame>
    <description>The ECG variables will be summarized by absolute value at each visit by treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)</time_frame>
    <description>To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed concentration (tmax)</measure>
    <time_frame>From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)</time_frame>
    <description>To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from 0 to the last measurable time point (AUC0-t)</measure>
    <time_frame>From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)</time_frame>
    <description>To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from 0 to infinity (AUC0-∞)</measure>
    <time_frame>From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)</time_frame>
    <description>To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)</time_frame>
    <description>To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at terminal phase (Vz/F)</measure>
    <time_frame>From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)</time_frame>
    <description>To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for concentration to decrease by 50% (concentration half-life) (t1/2)</measure>
    <time_frame>From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)</time_frame>
    <description>To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA) as determined by evaluation of ADA positive percentage and ADA negative percentage</measure>
    <time_frame>From Day 1 to Follow-UP ( Days 8, Days 15, Days 29, Days 92, Days 120, Days 155)</time_frame>
    <description>To assess the immunogenicity of SHR-1703</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1703 (Dose 1) or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1703 (Dose 2) or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1703 (Dose 3) or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1703 (Dose 4) or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1703 (Dose 5) or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1703</intervention_name>
    <description>SHR-1703</description>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 1</arm_group_label>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 2</arm_group_label>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 3</arm_group_label>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 4</arm_group_label>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of the SHR-1703</description>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 1</arm_group_label>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 2</arm_group_label>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 3</arm_group_label>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 4</arm_group_label>
    <arm_group_label>SHR-1703-Subcutaneous administration of Dose 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Able to read, comprehend and write at a sufficient level to complete study materials.&#xD;
&#xD;
          -  Aged 18 to 55 years (inclusive).&#xD;
&#xD;
          -  Body weight equal or more than 45.0 kg and BMI within the range between 19 and 24kg/m2&#xD;
             (inclusive).&#xD;
&#xD;
          -  AST, ALT, alkaline phosphatase and bilirubin equal or less than ULN.&#xD;
&#xD;
          -  Healthy Chinese as determined by a responsible and experienced physician, based on a&#xD;
             medical evaluation including medical history, physical examination, laboratory tests.&#xD;
             A subject with a clinical abnormality or laboratory parameters outside the reference&#xD;
             range for the population being studied may be included only if the Investigator and&#xD;
             the Jiangsu HengRui Medicine Co Medical Monitor agree that the finding is unlikely to&#xD;
             introduce additional risk factors and will not interfere with the study procedures.&#xD;
&#xD;
          -  Subjects must commit to consistent and correct use of an acceptable method of birth&#xD;
             control from the start of trial to the next month after the last visit.&#xD;
&#xD;
          -  A negative pre-study drug/alcohol screen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy/intolerance to the SHR-1703 and/or excipients in the formulation, or any other&#xD;
             Biologics&#xD;
&#xD;
          -  Positive Hepatitis B surface antigen or positive Hepatitis C antibody or human&#xD;
             immunodeficiency virus - HIV antibody or Syphilis serological test at screening&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to screening in the current study: 3&#xD;
             months, 5 half-lives or fellow-up period of the investigational product (whichever is&#xD;
             longer).&#xD;
&#xD;
          -  Use of any medicines, including prescription or Over-the-Counter drugs (including&#xD;
             herbal and dietary supplements, not including regular vitamins and paracetamol which&#xD;
             be used occasionally in the recommended dose) within 1 month or 5 half-lives&#xD;
             (whichever is longer) prior to the administration.&#xD;
&#xD;
          -  Subjects who have received immune inhibitors within 6 months prior to screening&#xD;
&#xD;
          -  Subjects who have had severe trauma or surgery within 6 months prior to screening, or&#xD;
             who plan to undergo surgery during the trial.&#xD;
&#xD;
          -  Blood donation history within 1 month prior to screening ,or severe blood loss(total&#xD;
             blood volume≥400 ml)，or blood transfusion within 2 months&#xD;
&#xD;
          -  Subjects who are inoculated live (attenuated) vaccine within 1 month prior to&#xD;
             screening or during the trial.&#xD;
&#xD;
          -  Subject who is an immediate family member of the participating investigator,&#xD;
             sub-investigator, study coordinator, or employee of the participating investigator.&#xD;
&#xD;
          -  At the discretion of the investigator, a subject will not be eligible for this study&#xD;
             if he/she is in the following cases: the subject is not able to complete the study, or&#xD;
             present a significant risk to the subject, or present other factors(e.g. infirmity.&#xD;
             etc.) that may prevent the enrolment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>November 10, 2022</last_update_submitted>
  <last_update_submitted_qc>November 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04480762
org study id: SHR-1703-101
nct id: NCT04480762
lead sponsor: 
is fda regulated drug: No
is fda regulated device: No
SHR-1703 is a monoclonal antibody under development for severe asthma. This study is the
      first study in Healthy subjects. The purpose of this study is to evaluate the safety,
      tolerability, pharmacokinetics and pharmacodynamics of a single dose SHR-1703 administered
      subcutaneously in Chinese healthy subjects.
This study will be conducted at 1 study center in China. Approximately 42 healthy Chinese
      male and female subjects, aged 18 to 55 inclusive, will be randomized to receive a single SC
      administration of SHR-1703: Treatment 1, Treatment 2, Treatment 3, Treatment 4 and Treatment
      5. Each subject will participate in only 1 treatment group. The total length of the study for
      each subject is up to 190 days (28 days of screening and 155+/- 7 days of further study
      visits).
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Number of participants with Adverse events (AEs) and serious adverse events (SAEs)
time frame: From Day 1 to Days 155
description: The number and percentage of subjects with treatment-emergent AE/SAE/AE by severity/drug-related AE/drug-related SAE/death in each dose level group and overall. AE/SAE will be displayed by MedDRA SOC and/or PT
measure: Safety as determined by abnormality in haematology
time frame: From Day 1 to Days 155
description: Measurement of red blood cell count, white blood cell count, haemoglobin and platelets
measure: Safety as determined by abnormality in clinical chemistry
time frame: From Day 1 to Days 155
description: Measurement of kidney function (e.g.urea ,creatinine, Uric acid), liver function(ALP, ALT, AST, albumin, total bilirubin), lipid profile(total cholesterol, triglycerides), ions.
measure: Safety as determined by abnormality in urinalysis
time frame: From Day 1 to Days 155
description: Measurement of glucose, ketones, leukocytes, blood and protein
measure: Safety as determined by evaluation of blood pressure in mmHg
time frame: From Day 1 to Days 155
description: Measurement of blood pressure (systolic and diastolic in mmHg)
measure: Safety as determined by evaluation of Pulse rate in beats per minute
time frame: From Day 1 to Days 155
description: Measurement of Pulse rate in beats per minute
measure: Safety as determined by evaluation of body temperature in degree Celsius
time frame: From Day 1 to Days 155
description: Measurement of body temperature in degree Celsius
measure: Safety as determined by evaluation of Respiratory rate in beats per minute
time frame: From Day 1 to Days 155
description: Measurement of Respiratory rate in beats per minute
measure: Safety as determined by analysis of 12-lead ECG variables: heart rate (beats per minute)
time frame: From Day 1 to Days 155
description: The ECG variables will be summarized by absolute value at each visit by treatment group, together with the corresponding changes from baseline.
measure: Safety as determined by analysis of 12-lead ECG variables: PR, QRS, QT and QTcF (milliseconds)
time frame: From Day 1 to Days 155
description: The ECG variables will be summarized by absolute value at each visit by treatment group.
measure: Maximum observed concentration (Cmax)
time frame: From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)
description: To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.
measure: Time to maximum observed concentration (tmax)
time frame: From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)
description: To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.
measure: Area under the concentration-time curve from 0 to the last measurable time point (AUC0-t)
time frame: From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)
description: To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.
measure: Area under the concentration-time curve from 0 to infinity (AUC0-∞)
time frame: From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)
description: To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.
measure: Apparent clearance (CL/F)
time frame: From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)
description: To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.
measure: Apparent volume of distribution at terminal phase (Vz/F)
time frame: From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)
description: To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.
measure: Time for concentration to decrease by 50% (concentration half-life) (t1/2)
time frame: From Day 1 to Follow-UP ( Days2, Days 3,Days 4, Days 5, Days 6, Days 8, Days 11, Days 15, Days 22 , Days 29, Days 43, Days 64, Days 92, Days 120, Days 155)
description: To assess the Pharmacokinetic profile of Subcutaneously administration of SHR-1703 in healthy Chinese subjects.
measure: Anti-drug antibody (ADA) as determined by evaluation of ADA positive percentage and ADA negative percentage
time frame: From Day 1 to Follow-UP ( Days 8, Days 15, Days 29, Days 92, Days 120, Days 155)
description: To assess the immunogenicity of SHR-1703
arm group label: SHR-1703-Subcutaneous administration of Dose 1
arm group type: Experimental
description: A single subcutaneous injection of SHR-1703 (Dose 1) or Placebo
arm group label: SHR-1703-Subcutaneous administration of Dose 2
arm group type: Experimental
description: A single subcutaneous injection of SHR-1703 (Dose 2) or Placebo
arm group label: SHR-1703-Subcutaneous administration of Dose 3
arm group type: Experimental
description: A single subcutaneous injection of SHR-1703 (Dose 3) or Placebo
arm group label: SHR-1703-Subcutaneous administration of Dose 4
arm group type: Experimental
description: A single subcutaneous injection of SHR-1703 (Dose 4) or Placebo
arm group label: SHR-1703-Subcutaneous administration of Dose 5
arm group type: Experimental
description: A single subcutaneous injection of SHR-1703 (Dose 5) or Placebo
intervention type: Drug
intervention name: SHR-1703
description: SHR-1703
arm group label: SHR-1703-Subcutaneous administration of Dose 1
arm group label: SHR-1703-Subcutaneous administration of Dose 2
arm group label: SHR-1703-Subcutaneous administration of Dose 3
arm group label: SHR-1703-Subcutaneous administration of Dose 4
arm group label: SHR-1703-Subcutaneous administration of Dose 5
intervention type: Drug
intervention name: Placebo
description: Placebo of the SHR-1703
arm group label: SHR-1703-Subcutaneous administration of Dose 1
arm group label: SHR-1703-Subcutaneous administration of Dose 2
arm group label: SHR-1703-Subcutaneous administration of Dose 3
arm group label: SHR-1703-Subcutaneous administration of Dose 4
arm group label: SHR-1703-Subcutaneous administration of Dose 5
criteria: 
gender: All
minimum age: 18 Years
maximum age: 55 Years
healthy volunteers: Accepts Healthy Volunteers
facility: 
country: China
responsible party type: Sponsor
sharing ipd: Undecided